Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Reg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Modern rheumatology 2024-03, Vol.34 (3), p.584-591
Hauptverfasser: Karakaş, Ali, Gulle, Semih, Can, Gerçek, Dalkılıc, Ediz, Akar, Servet, Koca, Suleyman Serdar, Pehlivan, Yavuz, Senel, Soner, Tufan, Abdurrahman, Ozturk, Mehmet Akif, Yilmaz, Sema, Yazici, Ayten, Cefle, Ayse, Yüce İnel, Tuba, Erez, Yesim, Sari, Ismail, Birlik, Merih, Direskeneli, Haner, Akkoc, Nurullah, Onen, Fatos
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Female
Humans
Male
Middle Aged
Obesity - complications
Spondylitis, Ankylosing - complications
Spondylitis, Ankylosing - drug therapy
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI)  .05). This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.
ISSN:1439-7595
1439-7609
DOI:10.1093/mr/road061